ChitogenX Management

Management criteria checks 2/4

ChitogenX's CEO is Pierre Laurin, appointed in Feb 2024, has a tenure of less than a year. directly owns 3.13% of the company’s shares, worth CA$104.22K. The average tenure of the management team and the board of directors is 5.7 years and 4.9 years respectively.

Key information

Pierre Laurin

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	3.1%
Management average tenure	5.7yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO

Pierre Laurin (62 yo)

less than a year

Tenure

Mr. Pierre Laurin, B.Sc.Pharm. M.Sc. serves as Chairman of ChitogenX Inc. since July 21, 2022 and serves as its Interim CEO since February 28, 2024. He serves as Independent Director at ChitogenX Inc. (for...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Pierre Laurin	Interim CEO & Independent Chairman	less than a year	no data	3.13% CA$ 104.2k
Luc Mainville	Senior VP & CFO	5.7yrs	CA$179.80k	6.04% CA$ 200.9k
Guy-Paul Allard	VP of Legal Affairs & Corporate Secretary	7.9yrs	no data	1.48% CA$ 49.4k
Jonathan Sackier	Senior Vice President of Medical Affairs	2yrs	CA$226.80k	0.76% CA$ 25.2k
Frederic Dumais	Director of Communications & Investor Relations	no data	no data	no data
Benedek Simo	Controller	5.7yrs	no data	no data

5.7yrs

Average Tenure

Experienced Management: CHGX's management team is seasoned and experienced (5.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Pierre Laurin	Interim CEO & Independent Chairman	4.9yrs	no data	3.13% CA$ 104.2k
Jack Farr	Member of Clinical Advisory Board	no data	no data	no data
Steven Saviuk	Director	9.3yrs	no data	0.10% CA$ 3.5k
Timothy Cunningham	Independent Director	2.9yrs	no data	no data
Scott Rodeo	Member of Clinical Advisory Board	no data	no data	no data
Patrick O'Donnell	Independent Director	3.3yrs	no data	no data
Brent Norton	Director	7.8yrs	no data	1.83% CA$ 60.8k
Martyn Snow	Member of Clinical Advisory Board	no data	no data	no data
Caroline Hoemann	Member of Scientific Advisory Board	no data	no data	4.35% CA$ 144.7k
Jacques Toueg	Member of Clinical Advisory Board	6.2yrs	no data	no data
Howard Walthall	Independent Director	2.9yrs	no data	no data

4.9yrs

Average Tenure

62yo

Average Age

Experienced Board: CHGX's board of directors are considered experienced (4.9 years average tenure).

ChitogenX Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

ChitogenX Inc., Annual General Meeting, Jul 19, 2023

High number of new directors

High number of new directors

President exercised options to buy CA$106k worth of stock.

Ortho Regenerative Technologies Inc. Announces Board Changes

Recent updates

New major risk - Revenue and earnings growth

Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal Study

New major risk - Financial position

Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Less than half of directors are independent

New major risk - Share price stability

ChitogenX Inc., Annual General Meeting, Jul 19, 2023

ChitogenX Inc. announced that it has received CAD 3.856348 million in funding

ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus Study

ChitogenX Inc. announced that it expects to receive CAD 6.1 million in funding

Chitogenx Successfully Completes Initial Portion of Its U.S. Phase I/Ii Rotator Cuff Repair Clinical Trial

ChitogenX Inc. Launches Second Orthopedic Development Program in Meniscus Repair

High number of new directors

Ortho Regenerative Technologies Inc. Announces Enrollment of First Patient in Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Ortho Regenerative Technologies Inc. Initiates Patients Recruitment for its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Ortho Regenerative Technologies Receives Key U.S. Composition and Method Patent for Ortho-R Soft Tissue Repair Platform

High number of new directors

Ortho Regenerative Technologies Inc. announced that it has received CAD 3.2 million in funding

Ortho Regenerative Technologies Inc. announced that it expects to receive CAD 3 million in funding

Ortho Regenerative Technologies Inc. Announces U.S. IND Clinical Hold Lifted by the FDA & Clearance to Proceed with U.S. Clinical Trial

Ortho Regenerative Technologies Announces Extension of FDA Clinical Hold of ORTHO-R Investigational New Drug Application

Ortho Regenerative Technologies Inc. Receives Clinical Hold Letter from the U.S. Food and Drug Administration

Forecast to breakeven in 2026

New 90-day low: CA$0.54

President exercised options to buy CA$106k worth of stock.

Ortho Regenerative Technologies Inc. Announces Board Changes

Ortho Regenerative Technologies Inc. Enters into Global Licensing Agreement with Hanuman Pelican Inc

Ortho Regenerative Technologies Inc. announced that it has received CAD 3 million in funding from Leede Jones Gable Inc.

New 90-day high: CA$0.74

Ortho Regenerative Technologies Inc. Announces Appointment of Mukesh Ahuja as Vice-President Clinical and Medical Affairs, Effective November 1, 2020

Ortho Regenerative Technologies Inc. announced that it has received CAD 0.1376 million in funding

Ortho Regenerative Technologies Inc. announced that it expects to receive CAD 0.2 million in funding

New 90-day high - CA$0.43

Ortho Regenerative Technologies Inc. announced that it has received CAD 2.47482 million in funding

Ortho Regenerative Technologies Inc. announced that it expects to receive CAD 0.64 million in funding

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age